Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Atea Pharmaceuticals
Biotech
Atea rejects 'undervalued' offer from Concentra
Concentra could have been forgiven for thinking their next acquisition weeks after Jounce would be another slam dunk. But Atea isn't playing ball.
James Waldron
May 30, 2023 7:51am
Concentra rebounds with a shot at COVID-19-focused Atea
May 22, 2023 11:20am
Atea dumps dengue drug as forecast R&D timelines, costs spiral
Mar 1, 2023 6:50am
Atea sticks it out with COVID antiviral and taps Merck HCV drug
Jan 7, 2022 9:50am
Atea will try to pair failed COVID-19 drug with other compounds
Dec 15, 2021 11:20am
Roche culls pandemic ties with Atea
Nov 17, 2021 7:30am